National Cancer Institute; Notice of Meeting, 30062-30063 [2021-11783]

Download as PDF 30062 Federal Register / Vol. 86, No. 106 / Friday, June 4, 2021 / Notices Contact Person: Lystranne Alysia Maynard Smith, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 402–4809, lystranne.maynard-smith@nih.gov. Name of Committee: Genes, Genomes, and Genetics Integrated Review Group; Therapeutic Approaches to Genetic Diseases Study Section. Date: June 30–July 1, 2021. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Elena Smirnova, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5187, MSC 7840, Bethesda, MD 20892, (301) 357– 9112, smirnove@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Physiology and Pathobiology of the Vascular and Hematological Systems. Date: June 30, 2021. Time: 9:30 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Larry Pinkus, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4132, MSC 7802, Bethesda, MD 20892, (301) 435– 1214, pinkusl@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cancer Biology. Date: June 30, 2021. Time: 1:00 p.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Juraj Bies, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 4158, MSC 7806, Bethesda, MD 20892, (301) 435–1256, biesj@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: June 1, 2021. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–11782 Filed 6–3–21; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 17:08 Jun 03, 2021 Jkt 253001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting AGENCY: National Institutes of Health, HHS. ACTION: Notice. The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a joint meeting with the National Institutes of Arthritis and Musculoskeletal and Skin Diseases on June 4, 2021. The topic for this meeting will be ‘‘Diabetes and Bone.’’ The meeting is open to the public. DATES: The meeting will be held on June 4, 2021 from 11 a.m. to 1:00 p.m. EDT. ADDRESSES: The meeting will be held via the online video conferencing Zoom. For details, and to register, please contact dmicc@mail.nih.gov. FOR FURTHER INFORMATION CONTACT: For further information concerning this meeting, including a draft agenda, see the DMICC website, www.diabetescommittee.gov, or contact Dr. B. Tibor Roberts, Executive Secretary of the Diabetes Mellitus Interagency Coordinating Committee, National Institute of Diabetes and Digestive and Kidney Diseases, 31 Center Drive, Building 31A, Room 9A19, MSC 2560, Bethesda, MD 20892– 2560, telephone: 301–496–6623; FAX: 301–480–6741; email: dmicc@ mail.nih.gov. SUMMARY: In accordance with 42 U.S.C.285c–3, the DMICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) comprising members of the Department of Health and Human Services and other federal agencies that support diabetes-related activities, facilitates cooperation, communication, and collaboration on diabetes among government entities. DMICC meetings, held several times a year, provide an opportunity for Committee members to learn about and discuss current and future diabetes programs in DMICC member organizations and to identify opportunities for collaboration. The June 4, 2021 DMICC meeting will focus on ‘‘Diabetes and Bone.’’ Any member of the public interested in presenting oral comments to the Committee should notify the contact person listed on this notice at least 5 days in advance of the meeting. Interested individuals and representatives or organizations should SUPPLEMENTARY INFORMATION: PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 submit a letter of intent, a brief description of the organization represented, and a written copy of their oral presentation in advance of the meeting. Only one representative of an organization will be allowed to present; oral comments and presentations will be limited to a maximum of 5 minutes. Printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the Committee by forwarding their statement to the contact person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Because of time constraints for the meeting, oral comments will be allowed on a first-come, first-serve basis. Members of the public who would like to receive email notification about future DMICC meetings should register for the listserv available on the DMICC website, www.diabetescommittee.gov. Dated: May 19, 2021. Bruce Tibor Roberts, Executive Secretary, DMICC, Office of Scientific Program and Policy Analysis, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. [FR Doc. 2021–11728 Filed 6–3–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors. The meeting will be held as a virtual meeting and is open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). A portion of the National Cancer Advisory Board meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and E:\FR\FM\04JNN1.SGM 04JNN1 Federal Register / Vol. 86, No. 106 / Friday, June 4, 2021 / Notices the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Advisory Board and NCI Board of Scientific Advisors. Date: June 14, 2021. Open: 11:00 a.m. to 12:00 p.m. Agenda: NCAB Subcommittee Meetings— Subcommittee on Planning and Budget. Open: 12:05 p.m. to 4:00 p.m. Agenda: Joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors, NCI Director’s report and presentations. Closed: 4:00 p.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting). Name of Committee: National Cancer Advisory Board and NCI Board of Scientific Advisors. Date: June 15, 2021. Open: 1:00 p.m. to 3:00 p.m. Agenda: Joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors, NCI Board of Scientific Advisors Concepts Review, Ongoing and New Business. Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting). Contact Person: Paulette S. Gray, Ph.D. Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Room. 7W444, Bethesda, MD 20892, 240–276–6340, grayp@ mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: NCAB: https://deainfo.nci.nih.gov/ advisory/ncab/ncabmeetings.htm, BSA: https://deainfo.nci.nih.gov/advisory/ bsa/bsameetings.htm, where an agenda and any additional information for the meeting will be posted when available. This notice is being published less than 15 days prior to the meeting due to scheduling difficulties. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) VerDate Sep<11>2014 17:08 Jun 03, 2021 Jkt 253001 Dated: June 1, 2021. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–11783 Filed 6–3–21; 8:45 am] 30063 DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency BILLING CODE 4140–01–P [Docket ID FEMA–2020–0016] DEPARTMENT OF HEALTH AND HUMAN SERVICES Meetings To Implement Pandemic Response Voluntary Agreement Under Section 708 of the Defense Production Act National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Cancer Institute. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, National Cancer Institute. Date: July 12–13, 2021. Time: 11:00 a.m. to 5:30 p.m. Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators. Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting). Contact Person: Brian E. Wojcik, Ph.D., Senior Review Administrator, Institute Review Office, Office of the Director, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W414, Rockville, MD 20850, 240–276–5660, wojcikb@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: June 1, 2021. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–11784 Filed 6–3–21; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 Federal Emergency Management Agency, Department of Homeland Security. ACTION: Announcement of meetings. AGENCY: The Federal Emergency Management Agency (FEMA) held two meetings to implement the Voluntary Agreement for the Manufacture and Distribution of Critical Healthcare Resources Necessary to Respond to a Pandemic. DATES: The first meeting took place on Tuesday, May 25, 2021, from 10:30 a.m. to 12 p.m. Eastern Time (ET). The second meeting took place on Wednesday, May 26, 2021, from 2 to 3 p.m. ET. FOR FURTHER INFORMATION CONTACT: Robert Glenn, Office of Business, Industry, Infrastructure Integration, via email at OB3I@fema.dhs.gov or via phone at (202) 212–1666. SUPPLEMENTARY INFORMATION: Notice of these meetings is provided as required by section 708(h)(8) of the Defense Production Act (DPA), 50 U.S.C. 4558(h)(8), and consistent with 44 CFR part 332. The DPA authorizes the making of ‘‘voluntary agreements and plans of action’’ with representatives of industry, business, and other interests to help provide for the national defense.1 The President’s authority to facilitate voluntary agreements with respect to responding to the spread of COVID–19 within the United States was delegated to the Secretary of Homeland Security in Executive Order 13911.2 The Secretary of Homeland Security further delegated this authority to the FEMA Administrator.3 On August 17, 2020, after the appropriate consultations with the Attorney General and the Chairman of the Federal Trade Commission, FEMA completed and published in the Federal Register a ‘‘Voluntary Agreement, Manufacture and Distribution of Critical Healthcare Resources Necessary to SUMMARY: 1 50 U.S.C. 4558(c)(1). FR 18403 (Apr. 1, 2020). 3 DHS Delegation 09052, Rev. 00.1 (Apr. 1, 2020); DHS Delegation Number 09052 Rev. 00 (Jan. 3, 2017). 2 85 E:\FR\FM\04JNN1.SGM 04JNN1

Agencies

[Federal Register Volume 86, Number 106 (Friday, June 4, 2021)]
[Notices]
[Pages 30062-30063]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-11783]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Cancer 
Advisory Board and NCI Board of Scientific Advisors.
    The meeting will be held as a virtual meeting and is open to the 
public as indicated below. Individuals who plan to view the virtual 
meeting and need special assistance or other reasonable accommodations 
to view the meeting should notify the Contact Person listed below in 
advance of the meeting. The meeting will be videocast and can be 
accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).
    A portion of the National Cancer Advisory Board meeting will be 
closed to the public in accordance with the provisions set forth in 
sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The 
grant applications and

[[Page 30063]]

the discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.

    Name of Committee: National Cancer Advisory Board and NCI Board 
of Scientific Advisors.
    Date: June 14, 2021.
    Open: 11:00 a.m. to 12:00 p.m.
    Agenda: NCAB Subcommittee Meetings--Subcommittee on Planning and 
Budget.
    Open: 12:05 p.m. to 4:00 p.m.
    Agenda: Joint meeting of the National Cancer Advisory Board and 
NCI Board of Scientific Advisors, NCI Director's report and 
presentations.
    Closed: 4:00 p.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute--Shady Grove, 9609 Medical 
Center Drive, Rockville, MD 20850 (Virtual Meeting).

    Name of Committee: National Cancer Advisory Board and NCI Board 
of Scientific Advisors.
    Date: June 15, 2021.
    Open: 1:00 p.m. to 3:00 p.m.
    Agenda: Joint meeting of the National Cancer Advisory Board and 
NCI Board of Scientific Advisors, NCI Board of Scientific Advisors 
Concepts Review, Ongoing and New Business.
    Place: National Cancer Institute--Shady Grove, 9609 Medical 
Center Drive, Rockville, MD 20850 (Virtual Meeting).
    Contact Person: Paulette S. Gray, Ph.D. Director, Division of 
Extramural Activities, National Cancer Institute--Shady Grove, 
National Institutes of Health, 9609 Medical Center Drive, 7th Floor, 
Room. 7W444, Bethesda, MD 20892, 240-276-6340, [email protected].
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page:
    NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm,
    BSA: https://deainfo.nci.nih.gov/advisory/bsa/bsameetings.htm, 
where an agenda and any additional information for the meeting will 
be posted when available.
    This notice is being published less than 15 days prior to the 
meeting due to scheduling difficulties.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: June 1, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-11783 Filed 6-3-21; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.